Table 2.
Patient characteristics of IBD patients with colorectal carcinoma versus sporadic colorectal carcinomas, Erlangen Registry of ColoRectal Carcinomas (ERCRC), n = 3773
| IBD-associated CRC (n = 63) | Sporadic CRC (n = 3710) | p-value | ||
|---|---|---|---|---|
| n (%) | n (%) | |||
| Age | Median (range) (years) | 45 (22–80) | 66 (18–99) | < 0.001 |
| Sex | Male | 35 (56) | 2315 (62.4) | 0.266 |
| Female | 28 (44) | 1395 (37.6) | ||
| ECOG* | ECOG 0–1 | 49 (85) | 2882 (84.8) | 0.953 |
| ECOG 2–4 | 9 (16) | 518 (15.2) | ||
| ASA** | ASA 1–2 | 49 (86) | 2422 (75.2) | 0.062 |
| ASA 3–4 | 8 (14) | 797 (21.5) | ||
| Tumor site | Right colon | 25 (40) | 863 (23.3) | 0.008 |
| Left colon | 12 (19) | 1060 (28.6) | ||
| Rectum | 26 (41) | 1787 (48.2) | ||
| Emergency surgery | Yes | 5 (8) | 246 (6.6) | 0.680 |
| No | 58 (92) | 3464 (93.4) | ||
| Surgery | TME/CME | 36 (57) | 3701 (99.8) | < 0.001 |
| (Procto)colectomy | 27 (43) | 9 (0.2) | ||
| Histological type | Adenocarcinoma | 51 (81) | 3370 (90.8) | 0.007 |
| Other types*** | 12 (19) | 340 (9.2) | ||
| Stage (UICC) | Stage I | 16 (26) | 748 (20.2) | 0.334 |
| Stage II | 17 (27) | 790 (21.3) | ||
| Stage III | 13 (21) | 717 (19.3) | ||
| Stage IV | 10 (16) | 585 (15.8) | ||
| Stage y0 | 0 | 98 (2.6) | ||
| Stage yI | 0 | 191 (5.2) | ||
| Stage yII | 2 (3) | 196 (5.3) | ||
| Stage yIII | 1 (2) | 202 (5.4) | ||
| Stage yIV | 3 (5) | 181 (4.9) | ||
| Distant metastases | M0 | 50 (79) | 2946 (79.4) | 0.993 |
| M1 | 13 (21) | 764 (20.6) | ||
| R classification | R0 | 51 (81) | 3097 (83.5) | 0.345 |
| R1 | 2 (3) | 53 (1.4) | ||
| R2 | 8 (13) | 515 (13.9) | ||
| RX | 2 (3) | 45 (1.2) | ||
| Multimodal treatment | Yes | 31 (49) | 1826 (50.8) | 0.998 |
| No | 32 (51) | 1884 (49.2) |
IBD inflammatory bowel disease, CRC colorectal carcinoma, ASA American Society of Anesthesiologists Classification, TME total mesorectal excision, CME complete mesorectal excision; *ECOG performance status in 315 patients unknown; **ASA missing in 497 patients; ***undifferentiated carcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, adenosquamous carcinoma. RX usually due to complete radio frequency ablation of liver metastases